<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>IPNA Online</title>
	<atom:link href="http://www.ipna-online.org/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.ipna-online.org</link>
	<description>International Pediatric Nephrology Association</description>
	<lastBuildDate>Wed, 16 May 2012 20:25:52 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Surgical management of vesicoureteral reflux in children</title>
		<link>http://www.ipna-online.org/2012/05/surgical-management-of-vesicoureteral-reflux-in-children/</link>
		<comments>http://www.ipna-online.org/2012/05/surgical-management-of-vesicoureteral-reflux-in-children/#comments</comments>
		<pubDate>Wed, 16 May 2012 20:25:52 +0000</pubDate>
		<dc:creator>linda</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Urinary Tract Disorders]]></category>

		<guid isPermaLink="false">http://www.ipna-online.org/?p=1893</guid>
		<description><![CDATA[





What is the success rate of endoscopic injection for treatment of VURa. 30-40%b. 50-60%c. 70-80%d. 90-95%What is the risk of renal scarring following first UTIa. 5%b. 10%c. 15%d. 25%All of the following are recommendations based on the 2010 AUA guidelines for the treatment of VUR, except:a. A VCUG should be performed following a febrile UTI [...]]]></description>
			<content:encoded><![CDATA[<p>
<div class="quiz-area single-page-quiz">
<form action="" method="post" class="quiz-form" id="quiz-146">
<div class='question' id='question-1'><div class='question-content'>What is the success rate of endoscopic injection for treatment of VUR</div><br /><input type='hidden' name='question_id[]' value='869' /><input type='radio' name='answer-869' id='answer-id-6272' class='answer' value='6272' /><label for='answer-id-6272'>a. 30-40%</label><br /><input type='radio' name='answer-869' id='answer-id-6273' class='answer' value='6273' /><label for='answer-id-6273'>b. 50-60%</label><br /><input type='radio' name='answer-869' id='answer-id-6274' class='answer' value='6274' /><label for='answer-id-6274'>c. 70-80%</label><br /><input type='radio' name='answer-869' id='answer-id-6275' class='answer' value='6275' /><label for='answer-id-6275'>d. 90-95%</label><br /></div><div class='question' id='question-2'><div class='question-content'>What is the risk of renal scarring following first UTI</div><br /><input type='hidden' name='question_id[]' value='870' /><input type='radio' name='answer-870' id='answer-id-6276' class='answer' value='6276' /><label for='answer-id-6276'>a. 5%</label><br /><input type='radio' name='answer-870' id='answer-id-6277' class='answer' value='6277' /><label for='answer-id-6277'>b. 10%</label><br /><input type='radio' name='answer-870' id='answer-id-6278' class='answer' value='6278' /><label for='answer-id-6278'>c. 15%</label><br /><input type='radio' name='answer-870' id='answer-id-6279' class='answer' value='6279' /><label for='answer-id-6279'>d. 25%</label><br /></div><div class='question' id='question-3'><div class='question-content'>All of the following are recommendations based on the 2010 AUA guidelines for the treatment of VUR, <em>except</em>:</div><br /><input type='hidden' name='question_id[]' value='871' /><input type='radio' name='answer-871' id='answer-id-6280' class='answer' value='6280' /><label for='answer-id-6280'>a. A VCUG should be performed following a febrile UTI in a child with prior successful endoscopic treatment</label><br /><input type='radio' name='answer-871' id='answer-id-6281' class='answer' value='6281' /><label for='answer-id-6281'>b. Surgical correction is recommended for patients on antibiotic prophylaxis with febrile break-through UTI</label><br /><input type='radio' name='answer-871' id='answer-id-6282' class='answer' value='6282' /><label for='answer-id-6282'>c. Either endoscopic or open repair of VUR are acceptable options for surgical correction</label><br /><input type='radio' name='answer-871' id='answer-id-6283' class='answer' value='6283' /><label for='answer-id-6283'>d. Endoscopic injection is effective for the treatment of grade 5 VUR</label><br /></div><div class='question' id='question-4'><div class='question-content'>The only factor which has been demonstrated to significantly influence DHA injection success rate is:</div><br /><input type='hidden' name='question_id[]' value='872' /><input type='radio' name='answer-872' id='answer-id-6284' class='answer' value='6284' /><label for='answer-id-6284'>a. Surgeon experience</label><br /><input type='radio' name='answer-872' id='answer-id-6285' class='answer' value='6285' /><label for='answer-id-6285'>b. Pre-operative VUR grade</label><br /><input type='radio' name='answer-872' id='answer-id-6286' class='answer' value='6286' /><label for='answer-id-6286'>c. Injection volume</label><br /><input type='radio' name='answer-872' id='answer-id-6287' class='answer' value='6287' /><label for='answer-id-6287'>d. Conflict of interest</label><br /></div><div class='question' id='question-5'><div class='question-content'>Which of the following is not true of endoscopic treatment of reflux:</div><br /><input type='hidden' name='question_id[]' value='873' /><input type='radio' name='answer-873' id='answer-id-6288' class='answer' value='6288' /><label for='answer-id-6288'>a. Entails injection of a bulking agent, allowing coaptation of the ureteral orifice</label><br /><input type='radio' name='answer-873' id='answer-id-6289' class='answer' value='6289' /><label for='answer-id-6289'>b. Sub-ureteral and intraureteral injection techniques have been described</label><br /><input type='radio' name='answer-873' id='answer-id-6290' class='answer' value='6290' /><label for='answer-id-6290'>c. Presence of bladder and bowel dysfunction does not affect the cure rate</label><br /><input type='radio' name='answer-873' id='answer-id-6291' class='answer' value='6291' /><label for='answer-id-6291'>d. Benefits include outpatient surgery and decreased patient morbidity</label><br /></div><br />
<input type="button" id="next-question" value="Next &gt;"  /><br />

<input type="submit" name="action" id="action-button" value="Show Results"  />
<input type="hidden" name="quiz_id" value="146" />
</form>
</div>

</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ipna-online.org/2012/05/surgical-management-of-vesicoureteral-reflux-in-children/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Renal involvement in mitochondrial cytopathies</title>
		<link>http://www.ipna-online.org/2012/05/renal-involvement-in-mitochondrial-cytopathies/</link>
		<comments>http://www.ipna-online.org/2012/05/renal-involvement-in-mitochondrial-cytopathies/#comments</comments>
		<pubDate>Wed, 16 May 2012 20:14:35 +0000</pubDate>
		<dc:creator>linda</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Chronic Kidney Disease]]></category>

		<guid isPermaLink="false">http://www.ipna-online.org/?p=1891</guid>
		<description><![CDATA[


Which of these statements is correct in respect to mtDNA:a. As opposed to nuclear DNA, mtDNA is single strandedb. Contains the nuclear information of all mitochondrial proteinsc. Mutations are always evenly distributed in cellsd.  It forms a circular string that varies in length among individuals e. None of the above is correctWhich of the [...]]]></description>
			<content:encoded><![CDATA[<p>
<div class="quiz-area single-page-quiz">
<form action="" method="post" class="quiz-form" id="quiz-145">
<div class='question' id='question-1'><div class='question-content'>Which of these statements is correct in respect to mtDNA:</div><br /><input type='hidden' name='question_id[]' value='864' /><input type='radio' name='answer-864' id='answer-id-6247' class='answer' value='6247' /><label for='answer-id-6247'>a. As opposed to nuclear DNA, mtDNA is single stranded</label><br /><input type='radio' name='answer-864' id='answer-id-6248' class='answer' value='6248' /><label for='answer-id-6248'>b. Contains the nuclear information of all mitochondrial proteins</label><br /><input type='radio' name='answer-864' id='answer-id-6249' class='answer' value='6249' /><label for='answer-id-6249'>c. Mutations are always evenly distributed in cells</label><br /><input type='radio' name='answer-864' id='answer-id-6250' class='answer' value='6250' /><label for='answer-id-6250'>d.  It forms a circular string that varies in length among individuals </label><br /><input type='radio' name='answer-864' id='answer-id-6251' class='answer' value='6251' /><label for='answer-id-6251'>e. None of the above is correct</label><br /></div><div class='question' id='question-2'><div class='question-content'>Which of the following organic acids is highly evocative of a renal mitochondrial cytopathy when found in excess in urine:</div><br /><input type='hidden' name='question_id[]' value='865' /><input type='radio' name='answer-865' id='answer-id-6252' class='answer' value='6252' /><label for='answer-id-6252'>a. 3 OH-butyrate</label><br /><input type='radio' name='answer-865' id='answer-id-6253' class='answer' value='6253' /><label for='answer-id-6253'>b. Succinate</label><br /><input type='radio' name='answer-865' id='answer-id-6254' class='answer' value='6254' /><label for='answer-id-6254'>c. Fumarate</label><br /><input type='radio' name='answer-865' id='answer-id-6255' class='answer' value='6255' /><label for='answer-id-6255'>d. Phenyl acetone</label><br /><input type='radio' name='answer-865' id='answer-id-6256' class='answer' value='6256' /><label for='answer-id-6256'>e. None of the above</label><br /></div><div class='question' id='question-3'><div class='question-content'>The most frequent renal disease in mitochondrial cytopathies is:</div><br /><input type='hidden' name='question_id[]' value='866' /><input type='radio' name='answer-866' id='answer-id-6257' class='answer' value='6257' /><label for='answer-id-6257'>a. Renal vascular disease</label><br /><input type='radio' name='answer-866' id='answer-id-6258' class='answer' value='6258' /><label for='answer-id-6258'>b. Chronic interstitial nephritis</label><br /><input type='radio' name='answer-866' id='answer-id-6259' class='answer' value='6259' /><label for='answer-id-6259'>c. Proximal tubulopathy</label><br /><input type='radio' name='answer-866' id='answer-id-6260' class='answer' value='6260' /><label for='answer-id-6260'>d. Glomerulopathy</label><br /><input type='radio' name='answer-866' id='answer-id-6261' class='answer' value='6261' /><label for='answer-id-6261'>e. None of the above</label><br /></div><div class='question' id='question-4'><div class='question-content'>Which of the following statements is correct:</div><br /><input type='hidden' name='question_id[]' value='867' /><input type='radio' name='answer-867' id='answer-id-6262' class='answer' value='6262' /><label for='answer-id-6262'>a. Clinical or subclinical renal involvement is always present in mitochondrial cytopathies</label><br /><input type='radio' name='answer-867' id='answer-id-6263' class='answer' value='6263' /><label for='answer-id-6263'>b. All patients with mitochondrial cytopathies have neuromuscular symptoms</label><br /><input type='radio' name='answer-867' id='answer-id-6264' class='answer' value='6264' /><label for='answer-id-6264'>c. Patients generally become symptomatic after the age of 5 years</label><br /><input type='radio' name='answer-867' id='answer-id-6265' class='answer' value='6265' /><label for='answer-id-6265'>d. FSGS lesions in patients with a maternal history of diabetes and deafness is evocative of a mutation of the tyrosine tRNA gene </label><br /><input type='radio' name='answer-867' id='answer-id-6266' class='answer' value='6266' /><label for='answer-id-6266'>e. None of the above</label><br /></div><div class='question' id='question-5'><div class='question-content'>Which of the following statements is correct:</div><br /><input type='hidden' name='question_id[]' value='868' /><input type='radio' name='answer-868' id='answer-id-6267' class='answer' value='6267' /><label for='answer-id-6267'>a. Mitochondrial coenzyme Q10 derives primarily from de novo synthesis </label><br /><input type='radio' name='answer-868' id='answer-id-6268' class='answer' value='6268' /><label for='answer-id-6268'>b. Coenzyme Q10 is present in the normal diet</label><br /><input type='radio' name='answer-868' id='answer-id-6269' class='answer' value='6269' /><label for='answer-id-6269'>c. Mutations in genes involved in the biosynthesis of coenzyme Q10 may cause NS </label><br /><input type='radio' name='answer-868' id='answer-id-6270' class='answer' value='6270' /><label for='answer-id-6270'>d. Symptoms related to coenzyme Q10 defects may be prevented by oral ubiquinone supplements </label><br /><input type='radio' name='answer-868' id='answer-id-6271' class='answer' value='6271' /><label for='answer-id-6271'>e. All of the above</label><br /></div><br />
<input type="button" id="next-question" value="Next &gt;"  /><br />

<input type="submit" name="action" id="action-button" value="Show Results"  />
<input type="hidden" name="quiz_id" value="145" />
</form>
</div>

</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ipna-online.org/2012/05/renal-involvement-in-mitochondrial-cytopathies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Surveillance biopsies in children post-kidney transplant</title>
		<link>http://www.ipna-online.org/2012/05/surveillance-biopsies-in-children-post-kidney-transplant/</link>
		<comments>http://www.ipna-online.org/2012/05/surveillance-biopsies-in-children-post-kidney-transplant/#comments</comments>
		<pubDate>Wed, 16 May 2012 20:01:45 +0000</pubDate>
		<dc:creator>linda</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Transplant]]></category>

		<guid isPermaLink="false">http://www.ipna-online.org/?p=1888</guid>
		<description><![CDATA[


The following statements about subclinical acute cellular rejection (SCR) are true except:a. The incidence of SCR is dependent on the amount and potency of immunosuppressionb. In adult renal transplant recipients, the incidence of SCR is decreasingc. In pediatric renal transplant recipients, the incidence of SCR is decreasingd. SCR is defined as Banff histology showing acute [...]]]></description>
			<content:encoded><![CDATA[<p>
<div class="quiz-area single-page-quiz">
<form action="" method="post" class="quiz-form" id="quiz-144">
<div class='question' id='question-1'><div class='question-content'>The following statements about subclinical acute cellular rejection (SCR) are true <strong>except</strong>:</div><br /><input type='hidden' name='question_id[]' value='858' /><input type='radio' name='answer-858' id='answer-id-6227' class='answer' value='6227' /><label for='answer-id-6227'>a. The incidence of SCR is dependent on the amount and potency of immunosuppression</label><br /><input type='radio' name='answer-858' id='answer-id-6228' class='answer' value='6228' /><label for='answer-id-6228'>b. In adult renal transplant recipients, the incidence of SCR is decreasing</label><br /><input type='radio' name='answer-858' id='answer-id-6229' class='answer' value='6229' /><label for='answer-id-6229'>c. In pediatric renal transplant recipients, the incidence of SCR is decreasing</label><br /><input type='radio' name='answer-858' id='answer-id-6230' class='answer' value='6230' /><label for='answer-id-6230'>d. SCR is defined as Banff histology showing acute rejection in patients with stable allograft function</label><br /></div><div class='question' id='question-2'><div class='question-content'>True or False: Acute subclinical rejection (A-SCR) is defined as acute rejection by Banff criteria (≥i2t2) with a concomitant increase in the serum creatinine.</div><br /><input type='hidden' name='question_id[]' value='859' /><input type='radio' name='answer-859' id='answer-id-6231' class='answer' value='6231' /><label for='answer-id-6231'>a. True</label><br /><input type='radio' name='answer-859' id='answer-id-6232' class='answer' value='6232' /><label for='answer-id-6232'>b. False</label><br /></div><div class='question' id='question-3'><div class='question-content'><div>True or False: Borderline subclinical rejection (B-SCR) is defined as acute rejection which does not meet Banff criteria (i0-i1 and/or t1-t3) without a concomitant increase in the serum creatinine.</div></div><br /><input type='hidden' name='question_id[]' value='860' /><input type='radio' name='answer-860' id='answer-id-6233' class='answer' value='6233' /><label for='answer-id-6233'>a. True</label><br /><input type='radio' name='answer-860' id='answer-id-6234' class='answer' value='6234' /><label for='answer-id-6234'>b. False</label><br /></div><div class='question' id='question-4'><div class='question-content'>The following are complications of surveillance biopsies <strong>except</strong>:</div><br /><input type='hidden' name='question_id[]' value='861' /><input type='radio' name='answer-861' id='answer-id-6235' class='answer' value='6235' /><label for='answer-id-6235'>a. Macroscopic hematuria</label><br /><input type='radio' name='answer-861' id='answer-id-6236' class='answer' value='6236' /><label for='answer-id-6236'>b. Arteriovenous fistula</label><br /><input type='radio' name='answer-861' id='answer-id-6237' class='answer' value='6237' /><label for='answer-id-6237'>c. Death</label><br /><input type='radio' name='answer-861' id='answer-id-6238' class='answer' value='6238' /><label for='answer-id-6238'>d. Bowel perforation</label><br /></div><div class='question' id='question-5'><div class='question-content'>All of the following increase the risk of post-biopsy hemorrhage <strong>except</strong>:</div><br /><input type='hidden' name='question_id[]' value='862' /><input type='radio' name='answer-862' id='answer-id-6239' class='answer' value='6239' /><label for='answer-id-6239'>a. Acute rejection with vascular involvement</label><br /><input type='radio' name='answer-862' id='answer-id-6240' class='answer' value='6240' /><label for='answer-id-6240'>b. Adult-sized kidney (ASK)</label><br /><input type='radio' name='answer-862' id='answer-id-6241' class='answer' value='6241' /><label for='answer-id-6241'>c. Penetration of the renal medulla</label><br /><input type='radio' name='answer-862' id='answer-id-6242' class='answer' value='6242' /><label for='answer-id-6242'>d. Use of a 16-gauge needle</label><br /></div><div class='question' id='question-6'><div class='question-content'>Which of the following lesions have been observed in surveillance biopsies?</div><br /><input type='hidden' name='question_id[]' value='863' /><input type='radio' name='answer-863' id='answer-id-6243' class='answer' value='6243' /><label for='answer-id-6243'>a. Acute cellular rejection</label><br /><input type='radio' name='answer-863' id='answer-id-6244' class='answer' value='6244' /><label for='answer-id-6244'>b. Interstitial fibrosis and tubular atrophy (IF/TA)</label><br /><input type='radio' name='answer-863' id='answer-id-6245' class='answer' value='6245' /><label for='answer-id-6245'>c. Transplant glomerulopathy (TG)</label><br /><input type='radio' name='answer-863' id='answer-id-6246' class='answer' value='6246' /><label for='answer-id-6246'>d. All of the above 
 

</label><br /></div><br />
<input type="button" id="next-question" value="Next &gt;"  /><br />

<input type="submit" name="action" id="action-button" value="Show Results"  />
<input type="hidden" name="quiz_id" value="144" />
</form>
</div>

</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ipna-online.org/2012/05/surveillance-biopsies-in-children-post-kidney-transplant/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Hypertensive crisis in children</title>
		<link>http://www.ipna-online.org/2012/05/hypertensive-crisis-in-children/</link>
		<comments>http://www.ipna-online.org/2012/05/hypertensive-crisis-in-children/#comments</comments>
		<pubDate>Wed, 16 May 2012 19:49:41 +0000</pubDate>
		<dc:creator>linda</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Hypertension]]></category>

		<guid isPermaLink="false">http://www.ipna-online.org/?p=1885</guid>
		<description><![CDATA[


The pathogenesis of hypertension in hypertensive crisis is all of the following except:a.  Increased activity of the renin angiotensin system b. Increased nitric oxide activityc. Increased sympathetic activityd. Endothelial dysfunctione. Decreased kininogen activityA 45-day-old premature infant who weighed 700 g at birth is being weaned from oxygen to room air. An ophthalmologist performed an [...]]]></description>
			<content:encoded><![CDATA[<p>
<div class="quiz-area single-page-quiz">
<form action="" method="post" class="quiz-form" id="quiz-143">
<div class='question' id='question-1'><div class='question-content'>The pathogenesis of hypertension in hypertensive crisis is all of the following except:</div><br /><input type='hidden' name='question_id[]' value='854' /><input type='radio' name='answer-854' id='answer-id-6199' class='answer' value='6199' /><label for='answer-id-6199'>a.  Increased activity of the renin angiotensin system </label><br /><input type='radio' name='answer-854' id='answer-id-6200' class='answer' value='6200' /><label for='answer-id-6200'>b. Increased nitric oxide activity</label><br /><input type='radio' name='answer-854' id='answer-id-6201' class='answer' value='6201' /><label for='answer-id-6201'>c. Increased sympathetic activity</label><br /><input type='radio' name='answer-854' id='answer-id-6202' class='answer' value='6202' /><label for='answer-id-6202'>d. Endothelial dysfunction</label><br /><input type='radio' name='answer-854' id='answer-id-6203' class='answer' value='6203' /><label for='answer-id-6203'>e. Decreased kininogen activity</label><br /></div><div class='question' id='question-2'><div class='question-content'>A 45-day-old premature infant who weighed 700 g at birth is being weaned from oxygen to room air. An ophthalmologist performed an eye exam. The infant was noted to have an acute increase in blood pressure from a baseline of 70/40 mmHg to 130/70 mmHg with tachycardia. The most likely etiology is:</div><br /><input type='hidden' name='question_id[]' value='855' /><input type='radio' name='answer-855' id='answer-id-6208' class='answer' value='6208' /><label for='answer-id-6208'>a. History of umbilical artery catheterization</label><br /><input type='radio' name='answer-855' id='answer-id-6209' class='answer' value='6209' /><label for='answer-id-6209'>b.  Development of broncho-pulmonary dysplasia </label><br /><input type='radio' name='answer-855' id='answer-id-6210' class='answer' value='6210' /><label for='answer-id-6210'>c. Phenylephrine eye drops</label><br /><input type='radio' name='answer-855' id='answer-id-6211' class='answer' value='6211' /><label for='answer-id-6211'>d. Renal parenchymal disease</label><br /><input type='radio' name='answer-855' id='answer-id-6212' class='answer' value='6212' /><label for='answer-id-6212'>e. Coarctation of aorta</label><br /></div><div class='question' id='question-3'><div class='question-content'>A 5-year-old female had a living donor kidney transplant. Seven days after the transplant she had a seizure. Her blood pressure was 170/120 mmHg, and her serum creatinine was 0.8 mg/dl. Calcineurin inhibitors were started on the third post-transplant day, and she was also started on mycophenolate mofetil. She is polyuric. What would you most likely expect to find upon investigation.</div><br /><input type='hidden' name='question_id[]' value='856' /><input type='radio' name='answer-856' id='answer-id-6217' class='answer' value='6217' /><label for='answer-id-6217'>a. Posterior reversible encephalopathy</label><br /><input type='radio' name='answer-856' id='answer-id-6218' class='answer' value='6218' /><label for='answer-id-6218'>b. Acute vascular rejection</label><br /><input type='radio' name='answer-856' id='answer-id-6219' class='answer' value='6219' /><label for='answer-id-6219'>c.  Fluid overload </label><br /><input type='radio' name='answer-856' id='answer-id-6220' class='answer' value='6220' /><label for='answer-id-6220'>d. Increased intracranial pressure</label><br /><input type='radio' name='answer-856' id='answer-id-6221' class='answer' value='6221' /><label for='answer-id-6221'>e. High mycophenolate mofetil levels</label><br /></div><div class='question' id='question-4'><div class='question-content'>An 8-year-old male has ESRD and is on hemodialysis. He had severe hypertension which improved with aggressive fluid removal and re-adjustment of his dry weight. His hypertension was managed with β blockers, clonidine and a calcium channel blocker. Blood pressures are now generally 110/80 mmHg. Which of the following would you consider as the next step.</div><br /><input type='hidden' name='question_id[]' value='857' /><input type='radio' name='answer-857' id='answer-id-6222' class='answer' value='6222' /><label for='answer-id-6222'>a. Wean clonidine</label><br /><input type='radio' name='answer-857' id='answer-id-6223' class='answer' value='6223' /><label for='answer-id-6223'>b. Stop calcium channel blocker</label><br /><input type='radio' name='answer-857' id='answer-id-6224' class='answer' value='6224' /><label for='answer-id-6224'>c. Increase β blocker</label><br /><input type='radio' name='answer-857' id='answer-id-6225' class='answer' value='6225' /><label for='answer-id-6225'>d. Increase dry weight</label><br /><input type='radio' name='answer-857' id='answer-id-6226' class='answer' value='6226' /><label for='answer-id-6226'>e. All of the above 
 

</label><br /></div><br />
<input type="button" id="next-question" value="Next &gt;"  /><br />

<input type="submit" name="action" id="action-button" value="Show Results"  />
<input type="hidden" name="quiz_id" value="143" />
</form>
</div>

</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ipna-online.org/2012/05/hypertensive-crisis-in-children/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Posterior reversible encephalopathy syndrome in children with kidney diseases</title>
		<link>http://www.ipna-online.org/2012/05/posterior-reversible-encephalopathy-syndrome-in-children-with-kidney-diseases/</link>
		<comments>http://www.ipna-online.org/2012/05/posterior-reversible-encephalopathy-syndrome-in-children-with-kidney-diseases/#comments</comments>
		<pubDate>Tue, 15 May 2012 20:03:01 +0000</pubDate>
		<dc:creator>linda</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Hypertension]]></category>

		<guid isPermaLink="false">http://www.ipna-online.org/?p=1882</guid>
		<description><![CDATA[ 


Symptoms of PRES include:a. Seizuresb. Headachec. Visual disturbanced. Altered consciousnesse. All the of the aboveWhich of the following agents is used for management of PRES?a. Steroidb.  Antihypertensive agents c. Immunoglobulind. Antibioticse. All of the aboveThe most sensitive modality for the diagnosis of PRES is:a. Cranial CTb. Cranial MRIc. Electroencephalographyd. Funduscopic examinatione. Cerebrospinal fluid studyPRES [...]]]></description>
			<content:encoded><![CDATA[<p> 
<div class="quiz-area single-page-quiz">
<form action="" method="post" class="quiz-form" id="quiz-142">
<div class='question' id='question-1'><div class='question-content'>Symptoms of PRES include:</div><br /><input type='hidden' name='question_id[]' value='849' /><input type='radio' name='answer-849' id='answer-id-6154' class='answer' value='6154' /><label for='answer-id-6154'>a. Seizures</label><br /><input type='radio' name='answer-849' id='answer-id-6155' class='answer' value='6155' /><label for='answer-id-6155'>b. Headache</label><br /><input type='radio' name='answer-849' id='answer-id-6156' class='answer' value='6156' /><label for='answer-id-6156'>c. Visual disturbance</label><br /><input type='radio' name='answer-849' id='answer-id-6157' class='answer' value='6157' /><label for='answer-id-6157'>d. Altered consciousness</label><br /><input type='radio' name='answer-849' id='answer-id-6158' class='answer' value='6158' /><label for='answer-id-6158'>e. All the of the above</label><br /></div><div class='question' id='question-2'><div class='question-content'>Which of the following agents is used for management of PRES?</div><br /><input type='hidden' name='question_id[]' value='850' /><input type='radio' name='answer-850' id='answer-id-6163' class='answer' value='6163' /><label for='answer-id-6163'>a. Steroid</label><br /><input type='radio' name='answer-850' id='answer-id-6164' class='answer' value='6164' /><label for='answer-id-6164'>b.  Antihypertensive agents </label><br /><input type='radio' name='answer-850' id='answer-id-6165' class='answer' value='6165' /><label for='answer-id-6165'>c. Immunoglobulin</label><br /><input type='radio' name='answer-850' id='answer-id-6166' class='answer' value='6166' /><label for='answer-id-6166'>d. Antibiotics</label><br /><input type='radio' name='answer-850' id='answer-id-6167' class='answer' value='6167' /><label for='answer-id-6167'>e. All of the above</label><br /></div><div class='question' id='question-3'><div class='question-content'>The most sensitive modality for the diagnosis of PRES is:</div><br /><input type='hidden' name='question_id[]' value='851' /><input type='radio' name='answer-851' id='answer-id-6172' class='answer' value='6172' /><label for='answer-id-6172'>a. Cranial CT</label><br /><input type='radio' name='answer-851' id='answer-id-6173' class='answer' value='6173' /><label for='answer-id-6173'>b. Cranial MRI</label><br /><input type='radio' name='answer-851' id='answer-id-6174' class='answer' value='6174' /><label for='answer-id-6174'>c. Electroencephalography</label><br /><input type='radio' name='answer-851' id='answer-id-6175' class='answer' value='6175' /><label for='answer-id-6175'>d. Funduscopic examination</label><br /><input type='radio' name='answer-851' id='answer-id-6176' class='answer' value='6176' /><label for='answer-id-6176'>e. Cerebrospinal fluid study</label><br /></div><div class='question' id='question-4'><div class='question-content'>PRES can develop in children with:</div><br /><input type='hidden' name='question_id[]' value='852' /><input type='radio' name='answer-852' id='answer-id-6181' class='answer' value='6181' /><label for='answer-id-6181'>a. Hemolytic uremic syndrome</label><br /><input type='radio' name='answer-852' id='answer-id-6182' class='answer' value='6182' /><label for='answer-id-6182'>b. Nephrotic syndrome</label><br /><input type='radio' name='answer-852' id='answer-id-6183' class='answer' value='6183' /><label for='answer-id-6183'>c. Kidney transplant</label><br /><input type='radio' name='answer-852' id='answer-id-6184' class='answer' value='6184' /><label for='answer-id-6184'>d. Acute poststreptococcal glomerulonephritis</label><br /><input type='radio' name='answer-852' id='answer-id-6185' class='answer' value='6185' /><label for='answer-id-6185'>e. All of the above</label><br /></div><div class='question' id='question-5'><div class='question-content'>The chief pathophysiological component of PRES is:</div><br /><input type='hidden' name='question_id[]' value='853' /><input type='radio' name='answer-853' id='answer-id-6190' class='answer' value='6190' /><label for='answer-id-6190'>a. Cytotoxic edema</label><br /><input type='radio' name='answer-853' id='answer-id-6191' class='answer' value='6191' /><label for='answer-id-6191'>b. Hemorrhage</label><br /><input type='radio' name='answer-853' id='answer-id-6192' class='answer' value='6192' /><label for='answer-id-6192'>c. Vasogenic edema</label><br /><input type='radio' name='answer-853' id='answer-id-6193' class='answer' value='6193' /><label for='answer-id-6193'>d. Infection</label><br /><input type='radio' name='answer-853' id='answer-id-6194' class='answer' value='6194' /><label for='answer-id-6194'>e. Degeneration of neurons  



</label><br /></div><br />
<input type="button" id="next-question" value="Next &gt;"  /><br />

<input type="submit" name="action" id="action-button" value="Show Results"  />
<input type="hidden" name="quiz_id" value="142" />
</form>
</div>

</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ipna-online.org/2012/05/posterior-reversible-encephalopathy-syndrome-in-children-with-kidney-diseases/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Epidemiology of chronic kidney disease in children</title>
		<link>http://www.ipna-online.org/2012/05/epidemiology-of-chronic-kidney-disease-in-children/</link>
		<comments>http://www.ipna-online.org/2012/05/epidemiology-of-chronic-kidney-disease-in-children/#comments</comments>
		<pubDate>Tue, 15 May 2012 19:49:00 +0000</pubDate>
		<dc:creator>linda</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Chronic Kidney Disease]]></category>

		<guid isPermaLink="false">http://www.ipna-online.org/?p=1879</guid>
		<description><![CDATA[


Which of the following statements regarding CKD is false?a. The KDOQI guidelines define CKD as a GFR ]]></description>
			<content:encoded><![CDATA[<p>
<div class="quiz-area single-page-quiz">
<form action="" method="post" class="quiz-form" id="quiz-141">
<div class='question' id='question-1'><div class='question-content'>Which of the following statements regarding CKD is false?</div><br /><input type='hidden' name='question_id[]' value='844' /><input type='radio' name='answer-844' id='answer-id-6120' class='answer' value='6120' /><label for='answer-id-6120'>a. The KDOQI guidelines define CKD as a GFR < 50 ml/min/1.73 m2 </label><br /><input type='radio' name='answer-844' id='answer-id-6121' class='answer' value='6121' /><label for='answer-id-6121'>b. GFR increases from birth and reaches adult values by 2 years of age</label><br /><input type='radio' name='answer-844' id='answer-id-6122' class='answer' value='6122' /><label for='answer-id-6122'>c. CAKUT is the major cause of CKD worldwide, although the proportion of glomerulonephritis in developing countries is higher due to infectious causes </label><br /><input type='radio' name='answer-844' id='answer-id-6123' class='answer' value='6123' /><label for='answer-id-6123'>d. There are few population-based studies in the early stages of CKD as it is often asymptomatic</label><br /></div><div class='question' id='question-2'><div class='question-content'>Which of the following statements regarding screening in children is true?</div><br /><input type='hidden' name='question_id[]' value='845' /><input type='radio' name='answer-845' id='answer-id-6124' class='answer' value='6124' /><label for='answer-id-6124'>a. Screening is currently recommended in children in the USA by the American Academy of Pediatrics</label><br /><input type='radio' name='answer-845' id='answer-id-6125' class='answer' value='6125' /><label for='answer-id-6125'>b. Screening has been proven to reduce the development of ESRD</label><br /><input type='radio' name='answer-845' id='answer-id-6126' class='answer' value='6126' /><label for='answer-id-6126'>c. Screening mainly employs dipsticks in children, as opposed to calculating GFR in adults</label><br /><input type='radio' name='answer-845' id='answer-id-6127' class='answer' value='6127' /><label for='answer-id-6127'>d. Urine dipstick testing is a cost-effective strategy for detecting CKD</label><br /></div><div class='question' id='question-3'><div class='question-content'>Which of the following statements regarding ESRD is false?</div><br /><input type='hidden' name='question_id[]' value='846' /><input type='radio' name='answer-846' id='answer-id-6132' class='answer' value='6132' /><label for='answer-id-6132'>a. Prevalence of ESRD is increasing owing to better overall survival and increased uptake of younger children and infants into RRT programs </label><br /><input type='radio' name='answer-846' id='answer-id-6133' class='answer' value='6133' /><label for='answer-id-6133'>b. The prevalence of RRT in 2008 in Australia, Canada, and western Europe (except Finland) is around 65 pmarp</label><br /><input type='radio' name='answer-846' id='answer-id-6134' class='answer' value='6134' /><label for='answer-id-6134'>c. Access to ESRD programs is highly dependent on socio-economic factors and as such, is limited in poorly developed countries</label><br /><input type='radio' name='answer-846' id='answer-id-6135' class='answer' value='6135' /><label for='answer-id-6135'>d. Incidence of ESRD varies depending on age and ethnic group</label><br /><input type='radio' name='answer-846' id='answer-id-6136' class='answer' value='6136' /><label for='answer-id-6136'>e. The majority of children are transplanted pre-emptively</label><br /></div><div class='question' id='question-4'><div class='question-content'>Which of the following regarding mortality and morbidity is false?</div><br /><input type='hidden' name='question_id[]' value='847' /><input type='radio' name='answer-847' id='answer-id-6137' class='answer' value='6137' /><label for='answer-id-6137'>a. The mortality rate has remained relatively unchanged in the last 15 years and is about 30 times higher than in healthy peers</label><br /><input type='radio' name='answer-847' id='answer-id-6138' class='answer' value='6138' /><label for='answer-id-6138'>b. Children on dialysis have a higher mortality rate compared with transplanted patients</label><br /><input type='radio' name='answer-847' id='answer-id-6139' class='answer' value='6139' /><label for='answer-id-6139'>c. Rejection is the main cause of admission in transplanted children</label><br /><input type='radio' name='answer-847' id='answer-id-6140' class='answer' value='6140' /><label for='answer-id-6140'>d.  20–40% of deaths in RRT are cardiovascular-related </label><br /></div><div class='question' id='question-5'><div class='question-content'>Which of the following statements regarding CKD progression is not true?</div><br /><input type='hidden' name='question_id[]' value='848' /><input type='radio' name='answer-848' id='answer-id-6145' class='answer' value='6145' /><label for='answer-id-6145'>a. Hypertension is a major risk factor for CKD progression</label><br /><input type='radio' name='answer-848' id='answer-id-6146' class='answer' value='6146' /><label for='answer-id-6146'>b. Hyperphosphatemia is an independent risk factor for CKD progression, as has been shown in prospective studies</label><br /><input type='radio' name='answer-848' id='answer-id-6147' class='answer' value='6147' /><label for='answer-id-6147'>c. There is evidence that the progression of CKD can be slowed by pharmacological intervention</label><br /><input type='radio' name='answer-848' id='answer-id-6148' class='answer' value='6148' /><label for='answer-id-6148'>d. The rate of CKD progression is inversely proportional to baseline GFR</label><br /><input type='radio' name='answer-848' id='answer-id-6149' class='answer' value='6149' /><label for='answer-id-6149'>e. Children with congenital disorders experience a slower progression of CKD than those with glomerulonephritis 
 

</label><br /></div><br />
<input type="button" id="next-question" value="Next &gt;"  /><br />

<input type="submit" name="action" id="action-button" value="Show Results"  />
<input type="hidden" name="quiz_id" value="141" />
</form>
</div>

</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ipna-online.org/2012/05/epidemiology-of-chronic-kidney-disease-in-children/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dyslipidemia in children with CKD: should we treat with statins?</title>
		<link>http://www.ipna-online.org/2012/05/dyslipidemia-in-children-with-ckd-should-we-treat-with-statins/</link>
		<comments>http://www.ipna-online.org/2012/05/dyslipidemia-in-children-with-ckd-should-we-treat-with-statins/#comments</comments>
		<pubDate>Tue, 15 May 2012 19:34:16 +0000</pubDate>
		<dc:creator>linda</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Chronic Kidney Disease]]></category>

		<guid isPermaLink="false">http://www.ipna-online.org/?p=1875</guid>
		<description><![CDATA[


Which of the risk factors for the development of CVD listed below are possible to treat in children with CKD?a. Disturbed calcium phosphate metabolismb. Dyslipidemiac.  Hypertension d. Obesitye. All of the aboveTreatment with a statin has convincingly been shown to improve mortality from CVDs in adult patientsa. In CKD stage 2b. On haemodialysisc. On [...]]]></description>
			<content:encoded><![CDATA[<p>
<div class="quiz-area single-page-quiz">
<form action="" method="post" class="quiz-form" id="quiz-140">
<div class='question' id='question-1'><div class='question-content'>Which of the risk factors for the development of CVD listed below are possible to treat in children with CKD?</div><br /><input type='hidden' name='question_id[]' value='839' /><input type='radio' name='answer-839' id='answer-id-6079' class='answer' value='6079' /><label for='answer-id-6079'>a. Disturbed calcium phosphate metabolism</label><br /><input type='radio' name='answer-839' id='answer-id-6080' class='answer' value='6080' /><label for='answer-id-6080'>b. Dyslipidemia</label><br /><input type='radio' name='answer-839' id='answer-id-6081' class='answer' value='6081' /><label for='answer-id-6081'>c.  Hypertension </label><br /><input type='radio' name='answer-839' id='answer-id-6082' class='answer' value='6082' /><label for='answer-id-6082'>d. Obesity</label><br /><input type='radio' name='answer-839' id='answer-id-6083' class='answer' value='6083' /><label for='answer-id-6083'>e. All of the above</label><br /></div><div class='question' id='question-2'><div class='question-content'>Treatment with a statin has convincingly been shown to improve mortality from CVDs in adult patients</div><br /><input type='hidden' name='question_id[]' value='840' /><input type='radio' name='answer-840' id='answer-id-6088' class='answer' value='6088' /><label for='answer-id-6088'>a. In CKD stage 2</label><br /><input type='radio' name='answer-840' id='answer-id-6089' class='answer' value='6089' /><label for='answer-id-6089'>b. On haemodialysis</label><br /><input type='radio' name='answer-840' id='answer-id-6090' class='answer' value='6090' /><label for='answer-id-6090'>c. On peritoneal dialysis</label><br /><input type='radio' name='answer-840' id='answer-id-6091' class='answer' value='6091' /><label for='answer-id-6091'>d. After a kidney transplant</label><br /><input type='radio' name='answer-840' id='answer-id-6092' class='answer' value='6092' /><label for='answer-id-6092'>e. All of the above</label><br /></div><div class='question' id='question-3'><div class='question-content'>The American Academy of Pediatrics recently recommended:</div><br /><input type='hidden' name='question_id[]' value='841' /><input type='radio' name='answer-841' id='answer-id-6097' class='answer' value='6097' /><label for='answer-id-6097'>a. Lipid screening in all children</label><br /><input type='radio' name='answer-841' id='answer-id-6098' class='answer' value='6098' /><label for='answer-id-6098'>b. Lipid screening in all children with one or more of defined risk factors for CVD</label><br /><input type='radio' name='answer-841' id='answer-id-6099' class='answer' value='6099' /><label for='answer-id-6099'>c. Treatment with a statin to be considered in all children older than 8 years with a confirmed LDL cholesterol level >4.9 mmol/L</label><br /><input type='radio' name='answer-841' id='answer-id-6100' class='answer' value='6100' /><label for='answer-id-6100'>d. Treatment with a statin to be considered in all children older than 8 years who have one of defined risk factors and a confirmed LDL cholesterol level >4.1 mmol/L </label><br /><input type='radio' name='answer-841' id='answer-id-6101' class='answer' value='6101' /><label for='answer-id-6101'>e. b, c and d.</label><br /></div><div class='question' id='question-4'><div class='question-content'>Which of the below statements is<strong> not</strong> true regarding a child with CKD?</div><br /><input type='hidden' name='question_id[]' value='842' /><input type='radio' name='answer-842' id='answer-id-6106' class='answer' value='6106' /><label for='answer-id-6106'>a. Has an increased risk to develop CVD</label><br /><input type='radio' name='answer-842' id='answer-id-6107' class='answer' value='6107' /><label for='answer-id-6107'>b. Should always have good blood pressure control</label><br /><input type='radio' name='answer-842' id='answer-id-6108' class='answer' value='6108' /><label for='answer-id-6108'>c. In many cases show increased levels of total and LDL cholesterol</label><br /><input type='radio' name='answer-842' id='answer-id-6109' class='answer' value='6109' /><label for='answer-id-6109'>d. Should have calcium phosphate balance carefully managed</label><br /><input type='radio' name='answer-842' id='answer-id-6110' class='answer' value='6110' /><label for='answer-id-6110'>e. Should routinely be treated with a statin if LDL cholesterol levels are increased</label><br /></div><div class='question' id='question-5'><div class='question-content'>Treatment data from adult patients with CKD are difficult to extrapolate to children, as:</div><br /><input type='hidden' name='question_id[]' value='843' /><input type='radio' name='answer-843' id='answer-id-6115' class='answer' value='6115' /><label for='answer-id-6115'>a. The diagnosis causing CKD in adults and children are very different</label><br /><input type='radio' name='answer-843' id='answer-id-6116' class='answer' value='6116' /><label for='answer-id-6116'>b. The child is growing and developing</label><br /><input type='radio' name='answer-843' id='answer-id-6117' class='answer' value='6117' /><label for='answer-id-6117'>c. There is a lack of long-term safety data in children</label><br /><input type='radio' name='answer-843' id='answer-id-6118' class='answer' value='6118' /><label for='answer-id-6118'>d. CVD normally becomes clinically overt when the child has grown up and been transferred to adult care</label><br /><input type='radio' name='answer-843' id='answer-id-6119' class='answer' value='6119' /><label for='answer-id-6119'>e. All of the above 
 

</label><br /></div><br />
<input type="button" id="next-question" value="Next &gt;"  /><br />

<input type="submit" name="action" id="action-button" value="Show Results"  />
<input type="hidden" name="quiz_id" value="140" />
</form>
</div>

</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ipna-online.org/2012/05/dyslipidemia-in-children-with-ckd-should-we-treat-with-statins/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>ICCS/ERIC/BAPU Congress 2012</title>
		<link>http://www.ipna-online.org/2012/04/iccs-eric-bapu-congress-2012/</link>
		<comments>http://www.ipna-online.org/2012/04/iccs-eric-bapu-congress-2012/#comments</comments>
		<pubDate>Mon, 09 Apr 2012 19:09:03 +0000</pubDate>
		<dc:creator>fvuong</dc:creator>
				<category><![CDATA[Congresses]]></category>

		<guid isPermaLink="false">http://www.ipna-online.org/?p=1848</guid>
		<description><![CDATA[[ October 12, 2012 to October 14, 2012. ] Location: Royal College of Physicians, London

The abstract submission deadline is 31st May 2012 at Midnight. For direct information about the abstract click here.

For more information about this event: www.iccs-eric-bapu.org.uk/]]></description>
			<content:encoded><![CDATA[<table class="ec3_schedule"><tr><td class="ec3_start">October 12, 2012</td><td class="ec3_to">to</td><td class="ec3_end">October 14, 2012</td></tr></table><p><strong>Location: </strong>Royal College of Physicians, London</p>
<p>The abstract submission deadline is 31st May 2012 at Midnight. For direct information about the abstract click <a href="http://www.iccs-eric-bapu.org.uk/?page_id=27" target="_blank">here</a>.</p>
<p>For more information about this event: <a href="www.iccs-eric-bapu.org.uk" target="_blank">www.iccs-eric-bapu.org.uk/</a></p>
]]></content:encoded>
			<wfw:commentRss>http://www.ipna-online.org/2012/04/iccs-eric-bapu-congress-2012/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Resistance to erythropoietin-stimulating agents: etiology, evaluation, and therapeutic considerations</title>
		<link>http://www.ipna-online.org/2012/04/resistance-to-erythropoietin-stimulating-agents-etiology-evaluation-and-therapeutic-considerations/</link>
		<comments>http://www.ipna-online.org/2012/04/resistance-to-erythropoietin-stimulating-agents-etiology-evaluation-and-therapeutic-considerations/#comments</comments>
		<pubDate>Tue, 03 Apr 2012 19:01:53 +0000</pubDate>
		<dc:creator>linda</dc:creator>
				<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Anemia]]></category>

		<guid isPermaLink="false">http://www.ipna-online.org/?p=1839</guid>
		<description><![CDATA[


One of the following is not a risk factor for ESA resistance:a. Primary hyperparathyroidismb. Occult GI bleedingc. Folate deficiencyd. Parvovirus B19e. Chlorinated dialysis waterMicrocytic anemia occurs in all of the following except:a. Lead toxicityb. Iron deficiencyc. Ascorbic acid deficiencyd. Copper deficiencye. Diphyllobothrium worm infestationWhich of the following statements concerning the association of fatality and use [...]]]></description>
			<content:encoded><![CDATA[<p>
<div class="quiz-area single-page-quiz">
<form action="" method="post" class="quiz-form" id="quiz-139">
<div class='question' id='question-1'><div class='question-content'>One of the following is not a risk factor for ESA resistance:</div><br /><input type='hidden' name='question_id[]' value='832' /><input type='radio' name='answer-832' id='answer-id-6016' class='answer' value='6016' /><label for='answer-id-6016'>a. Primary hyperparathyroidism</label><br /><input type='radio' name='answer-832' id='answer-id-6017' class='answer' value='6017' /><label for='answer-id-6017'>b. Occult GI bleeding</label><br /><input type='radio' name='answer-832' id='answer-id-6018' class='answer' value='6018' /><label for='answer-id-6018'>c. Folate deficiency</label><br /><input type='radio' name='answer-832' id='answer-id-6019' class='answer' value='6019' /><label for='answer-id-6019'>d. Parvovirus B19</label><br /><input type='radio' name='answer-832' id='answer-id-6020' class='answer' value='6020' /><label for='answer-id-6020'>e. Chlorinated dialysis water</label><br /></div><div class='question' id='question-2'><div class='question-content'>Microcytic anemia occurs in all of the following except:</div><br /><input type='hidden' name='question_id[]' value='833' /><input type='radio' name='answer-833' id='answer-id-6025' class='answer' value='6025' /><label for='answer-id-6025'>a. Lead toxicity</label><br /><input type='radio' name='answer-833' id='answer-id-6026' class='answer' value='6026' /><label for='answer-id-6026'>b. Iron deficiency</label><br /><input type='radio' name='answer-833' id='answer-id-6027' class='answer' value='6027' /><label for='answer-id-6027'>c. Ascorbic acid deficiency</label><br /><input type='radio' name='answer-833' id='answer-id-6028' class='answer' value='6028' /><label for='answer-id-6028'>d. Copper deficiency</label><br /><input type='radio' name='answer-833' id='answer-id-6029' class='answer' value='6029' /><label for='answer-id-6029'>e. Diphyllobothrium worm infestation</label><br /></div><div class='question' id='question-3'><div class='question-content'>Which of the following statements concerning the association of fatality and use of ESA is correct?</div><br /><input type='hidden' name='question_id[]' value='834' /><input type='radio' name='answer-834' id='answer-id-6034' class='answer' value='6034' /><label for='answer-id-6034'>a. Larger doses of ESA required to increase hemoglobin within the KDOQI target</label><br /><input type='radio' name='answer-834' id='answer-id-6035' class='answer' value='6035' /><label for='answer-id-6035'>b. Larger doses of ESA required to increase hemoglobin in excess of 40%</label><br /><input type='radio' name='answer-834' id='answer-id-6036' class='answer' value='6036' /><label for='answer-id-6036'>c. No change in ESA requirement, but unable to attain the K/DOQI target</label><br /><input type='radio' name='answer-834' id='answer-id-6037' class='answer' value='6037' /><label for='answer-id-6037'>d. Lower doses of ESA while there is an increase in Hb above the K/DOQI target</label><br /><input type='radio' name='answer-834' id='answer-id-6038' class='answer' value='6038' /><label for='answer-id-6038'>e. Attain K/DOQI target hemoglobin with intravenous iron only</label><br /></div><div class='question' id='question-4'><div class='question-content'>The mechanism of ESA resistance in CKD includes all the following except:</div><br /><input type='hidden' name='question_id[]' value='835' /><input type='radio' name='answer-835' id='answer-id-6043' class='answer' value='6043' /><label for='answer-id-6043'>a. Impaired EPO synthesis</label><br /><input type='radio' name='answer-835' id='answer-id-6044' class='answer' value='6044' /><label for='answer-id-6044'>b. Erythroid cell deficiency</label><br /><input type='radio' name='answer-835' id='answer-id-6045' class='answer' value='6045' /><label for='answer-id-6045'>c. Oxidative stress</label><br /><input type='radio' name='answer-835' id='answer-id-6046' class='answer' value='6046' /><label for='answer-id-6046'>d. Inflammatory cytokine</label><br /><input type='radio' name='answer-835' id='answer-id-6047' class='answer' value='6047' /><label for='answer-id-6047'>e. Circulating antibodies</label><br /></div><div class='question' id='question-5'><div class='question-content'>All are reasons for larger doses of ESA requirement in children except:</div><br /><input type='hidden' name='question_id[]' value='836' /><input type='radio' name='answer-836' id='answer-id-6052' class='answer' value='6052' /><label for='answer-id-6052'>a. Lower bone marrow response to EPO</label><br /><input type='radio' name='answer-836' id='answer-id-6053' class='answer' value='6053' /><label for='answer-id-6053'>b. Greater incidence of infection</label><br /><input type='radio' name='answer-836' id='answer-id-6054' class='answer' value='6054' /><label for='answer-id-6054'>c. Greater inflammatory status</label><br /><input type='radio' name='answer-836' id='answer-id-6055' class='answer' value='6055' /><label for='answer-id-6055'>d. Greater ESA prescription by physicians</label><br /><input type='radio' name='answer-836' id='answer-id-6056' class='answer' value='6056' /><label for='answer-id-6056'>e. Use of HD catheters</label><br /></div><div class='question' id='question-6'><div class='question-content'>All are effective interventions in the modulation of oxidative stress except:</div><br /><input type='hidden' name='question_id[]' value='837' /><input type='radio' name='answer-837' id='answer-id-6061' class='answer' value='6061' /><label for='answer-id-6061'>a. Vitamin C</label><br /><input type='radio' name='answer-837' id='answer-id-6062' class='answer' value='6062' /><label for='answer-id-6062'>b. Discontinuation of the hemodialysis catheter</label><br /><input type='radio' name='answer-837' id='answer-id-6063' class='answer' value='6063' /><label for='answer-id-6063'>c. Angiotensin-converting enzyme inhibition</label><br /><input type='radio' name='answer-837' id='answer-id-6064' class='answer' value='6064' /><label for='answer-id-6064'>d. Folate therapy</label><br /><input type='radio' name='answer-837' id='answer-id-6065' class='answer' value='6065' /><label for='answer-id-6065'>e. Transplant nephrectomy</label><br /></div><div class='question' id='question-7'><div class='question-content'>Mechanism of anemia due to mycophenolate mofetil (MMF):
<table>
<tbody>
<tr valign="top">
<td>1. </td>
<td>
<div>Inhibition of type II inosine monophosphate dehydrogenase</div></td>
</tr>
<tr valign="top">
<td>2. </td>
<td>
<div>Single nucleotide polymorphisms (SNPs) for uridine glucuronosyl-transferase 1A9</div></td>
</tr>
<tr valign="top">
<td>3. </td>
<td>
<div>Suppression of catalase enzyme</div></td>
</tr>
<tr valign="top">
<td>4. </td>
<td>
<div>Mitochondrial injury</div></td>
</tr>
</tbody>
</table></div><br /><input type='hidden' name='question_id[]' value='838' /><input type='radio' name='answer-838' id='answer-id-6070' class='answer' value='6070' /><label for='answer-id-6070'>a. 1, 2, 3</label><br /><input type='radio' name='answer-838' id='answer-id-6071' class='answer' value='6071' /><label for='answer-id-6071'>b. 1, 2</label><br /><input type='radio' name='answer-838' id='answer-id-6072' class='answer' value='6072' /><label for='answer-id-6072'>c. 3 only</label><br /><input type='radio' name='answer-838' id='answer-id-6073' class='answer' value='6073' /><label for='answer-id-6073'>d. 2 only</label><br /><input type='radio' name='answer-838' id='answer-id-6074' class='answer' value='6074' /><label for='answer-id-6074'>e. 2, 4 
 

</label><br /></div><br />
<input type="button" id="next-question" value="Next &gt;"  /><br />

<input type="submit" name="action" id="action-button" value="Show Results"  />
<input type="hidden" name="quiz_id" value="139" />
</form>
</div>

</p>
]]></content:encoded>
			<wfw:commentRss>http://www.ipna-online.org/2012/04/resistance-to-erythropoietin-stimulating-agents-etiology-evaluation-and-therapeutic-considerations/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>San Diego Growth Symposium</title>
		<link>http://www.ipna-online.org/2012/04/san-diego-growth-symposium/</link>
		<comments>http://www.ipna-online.org/2012/04/san-diego-growth-symposium/#comments</comments>
		<pubDate>Mon, 02 Apr 2012 22:41:22 +0000</pubDate>
		<dc:creator>fvuong</dc:creator>
				<category><![CDATA[Congresses]]></category>

		<guid isPermaLink="false">http://www.ipna-online.org/?p=1831</guid>
		<description><![CDATA[[ April 13, 2012 1:00 pm to April 14, 2012 6:15 pm. ] Location: San Diego, California 

For more information: http://ipnagrowthsymposium.org/]]></description>
			<content:encoded><![CDATA[<table class="ec3_schedule"><tr><td class="ec3_start">April 13, 2012 1:00 pm</td><td class="ec3_to">to</td><td class="ec3_end">April 14, 2012 6:15 pm</td></tr></table><p><strong>Location: </strong>San Diego, California </p>
<p><strong>For more information: <a href="http://ipnagrowthsymposium.org/" target="_blank">http://ipnagrowthsymposium.org/</a></strong></p>
]]></content:encoded>
			<wfw:commentRss>http://www.ipna-online.org/2012/04/san-diego-growth-symposium/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

